Bathla Group Hires Administrators as Australia Housing Slump Deepens 
BNP Paribas, KB Kookmin Eye $2 Billion Techcombank Stake 
Luxshare Shares Rise as First-Half Profit Jumps 18% 
Samsung Shares Tumble 8% as $79 Billion Return Plan Disappoints 
SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim 
Adidas, Puma Shares Fall as Dick’s Sporting Goods Cuts Outlook 
Ampol Profit Surges as Refining Margins Hit Record Highs 
J.P. Morgan Upgrades Diploma, Lifts Price Target to 8,250p 
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse 
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny 
SK Hynix Shares Fall as Workers Reject Wage Deal 
Xiaomi Unveils Xring O3 Chip for Flagship Foldable Phone 
Nvidia Eyes Perplexity Investment at $30 Billion Valuation 
OpenAI Data Center Chief Chris Malone Exits Ahead of Planned 2027 Listing 
SoftBank Plans Record $6.3 Billion Bond Sale to Fund OpenAI Investments 
Tesla Raises Cybertruck Prices by $5,000 in US 
SoftBank Eyes $20 Billion Bond Sale to Refinance OpenAI Loan 
Add as a preferred source on Google
DURHAM, N.C., April 30, 2018 -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals for the growing population of immunocompromised patients, today announced that it will host a live conference call and audio webcast on Monday, May 7, 2018 at 8:30 a.m. ET to report financial results for the first quarter ended March 31, 2018, and to provide a business overview.
To access the live conference call, please dial (877) 354-4056 (domestic) or (678) 809-1043 (international) at least five minutes prior to the start time and refer to conference ID 6173279. A live audio webcast of the call and accompanying slide presentation will also be available on the Investors’ section of the Company's website, www.chimerix.com. An archived webcast and accompanying slides will be available on the Chimerix website approximately two hours after the event.
About Chimerix
Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients. Chimerix's proprietary lipid conjugate technology and compound library have produced brincidofovir (BCV, CMX001); CMX157, which was licensed to ContraVir Pharmaceuticals; and a new clinical candidate, CMX521, the first direct-acting antiviral specifically for the treatment and prevention of norovirus. For further information, please visit Chimerix's website, www.chimerix.com.
CONTACT:
Investor Relations:
Michelle LaSpaluto
(919) 972-7115
[email protected]
or
Will O’Connor
Stern Investor Relations
[email protected]
212-362-1200
Media:
Becky Vonsiatsky
W2O Group
[email protected]
413-478-2003
